Innocan Pharma Corporation announced that is has reached a key milestone: the Company submitted its letter of application for a Pre-IND meeting, the first phase in the FDA approval process in the United States for Innocan's Liposome-Cannabidiol (LPT-CBD) injectable treatment of chronic pain. Innocan's therapy has shown consistent efficacy in multiple pre-clinical trials in recent years of it's LPT-CBD injectable treatment through prolonged and controlled release of CBD in animals with chronic pain conditions. Innocan's Pre-IND Meeting Request Letter to the FDA is a key milestone and important first step in seeking approval of its LPT-CBD therapy for use in humans.

At the Pre-IND meeting, the objective will be to obtain guidance from the FDA on the preclinical and clinical development plan, enabling the initiation of an Investigational New Drug (IND) program in the United States.